Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patientsMirjam Fässler(Kantonsspital St. Gallen), Lukas Flatz(University of Zurich)Journal for ImmunoTherapy of CancerFebruary 20, 201910.1186/s40425-019-0523-2Cited by 85SaveCiteExport RISWatch citationsRelated PapersIgA autoantibodies target pulmonary surfactant in patients with severe COVID-19|medRxiv|2021|6Cancer immunoediting by melanocyte differentiation antigen-specific T cells determines response to immune checkpoint inhibition|Research Square|2021|0